Factors predictive of endometrial carcinoma in patients with atypical endometrial hyperplasia on preoperative histology

Anticancer Research

Volumn 34, Issue 10, 2014, Pages 5671-5676

  Touboul, Cyril ^a,e   Piel, Bruno ^a   Koskas, Martin ^c   Gonthier, Clémentine ^c   Ballester, Marcos ^a,b   Cortez, Annie ^a   Daraï, Emile ^a,b,d  

^a HÔPITAL TENON   (France)

^b INSERM   (France)

^c BICHAT HOSPITAL   (France)

^d INSTITUT UNIVERSITAIRE DE FRANCE   (France)

^e UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

Atypical endometrial hyperplasia; Endometrial biopsy; Endometrial cancer; Hysteroscopy

Indexed keywords

ANAMNESIS; ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; COHORT ANALYSIS; CURETTAGE; ENDOMETRIAL THICKNESS; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; HYSTERECTOMY; HYSTEROSCOPY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; OBESITY; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; POSTMENOPAUSE; RETROSPECTIVE STUDY; UTERUS CAVITY; AGED; BIOPSY; CANCER GRADING; COMPLICATION; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; INCIDENCE; MENOPAUSE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RISK FACTOR;

AGED; BIOPSY; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; INCIDENCE; MENOPAUSE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84917695048     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ, 2nd, Alberts D and Curtin J: Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106: 812-819, 2006.
2. Kurman RJ and Norris HJ: Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer 49: 2547-2559, 1982.
3. Antonsen SL, Ulrich L and Hogdall C: Patients with atypical hyperplasia of the endometrium should be treated in oncological centers. Gynecol Oncol 125: 124-128, 2012.
4. Morotti M, Menada MV, Moioli M, Sala P, Maffeo I, Abete L, Fulcheri E, Menoni S, Venturini P and Papadia A: Frozen section pathology at time of hysterectomy accurately predicts endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia. Gynecol Oncol 125: 536-540, 2012.
5. Koskas M, Azria E, Walker F, Luton D, Madelenat P and Yazbeck C: Progestin treatment of atypical hyperplasia and well-differentiated adenocarcinoma of the endometrium to preserve fertility. Anticancer Res 32: 1037-1043, 2012.
6. Corrado G, Baiocco E, Carosi M and Vizza E: Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report. Fertil Steril 90: 2006 e2005-2008, 2008.
7. Tavassoli F and Devilee P: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs: IARC Press: Lyon, 2003.
8. Xie X, Lu WG, Ye DF, Chen HZ and Fu YF: The value of curettage in diagnosis of endometrial hyperplasia. Gynecol Oncol 84: 135-139, 2002.
9. Shutter J and Wright TC Jr.: Prevalence of underlying adenocarcinoma in women with atypical endometrial hyperplasia. Int J Gynecol Pathol 24: 313-318, 2005.
10. Suh-Burgmann E, Hung YY and Armstrong MA: Complex atypical endometrial hyperplasia: the risk of unrecognized adenocarcinoma and value of preoperative dilation and curettage. Obstet Gynecol 114: 523-529, 2009.
11. Giede KC, Yen TW, Chibbar R and Pierson RA: Significance of concurrent endometrial cancer in women with a preoperative diagnosis of atypical endometrial hyperplasia. J Obstet Gynaecol Can 30: 896-901, 2008.
12. Merisio C, Berretta R, De Ioris A, Pultrone DC, Rolla M, Giordano G, Tateo S and Melpignano M: Endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol 122: 107-111, 2005.
13. Hahn HS, Chun YK, Kwon YI, Kim TJ, Lee KH, Shim JU, Mok JE and Lim KT: Concurrent endometrial carcinoma following hysterectomy for atypical endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol 150: 80-83, 2010.
14. Ploteau S, Squifflet JL, Berliere M, Marbaix E and Donnez J: [Incidence of endometrial carcinoma after hysterectomy for atypical hyperplasia or FIGO stage IA carcinoma diagnosed on endometrial biopsy or endometrial resection]. Bull Cancer 95: 556-562, 2008.
15. Miller C, Bidus MA, Pulcini JP, Maxwell GL, Cosin JA and Rose GS: The ability of endometrial biopsies with atypical complex hyperplasia to guide surgical management. Am J Obstet Gynecol 199: 69 e61-64, 2008.
16. Garuti G, Mirra M and Luerti M: Hysteroscopic view in atypical endometrial hyperplasias: A correlation with pathologic findings on hysterectomy specimens. J Minim Invasive Gynecol 13: 325-330, 2006.
17. Agostini A, Cravello L, Shojai R, Schaeffer V, Bretelle F, Roger V and Blanc B: Risk of finding an endometrial cancer when atypical hyperplasia was incidentally diagnosed on hysteroscopic resection products. Eur J Obstet Gynecol Reprod Biol 103: 58-59, 2002.
18. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, Angioli R, Tateo S, Mangili G, Katsaros D, Garozzo G, Campagnutta E, Donadello N, Greggi S, Melpignano M, Raspagliesi F, Ragni N, Cormio G, Grassi R, Franchi M, Giannarelli D, Fossati R, Torri V, Amoroso M, Croce C and Mangioni C: Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100: 1707-1716, 2008.
19. Kitchener H, Swart AM, Qian Q, Amos C and Parmar MK: Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373: 125-136, 2009.
20. Ballester M, Dubernard G, Lecuru F, Heitz D, Mathevet P, Marret H, Querleu D, Golfier F, Leblanc E, Rouzier R and Darai E: Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol 12: 469-476, 2011.